• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Pfizer

Pfizer

Pfizer Inc PFE

Last Price$35.45Day Change (%)-0.28%
Open Price$35.66Day Change ($)-0.10
Day Range35.35–35.6652-Week Range29.83–35.84

As of Tue 9/19/2017 6:47:00 PM | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER Trial of XTANDI (enzalutamide) in Patients with Non-Metastatic Castration-Resistant Prostate Cancer

    Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER Trial of XTANDI (enzalutamide) in Patients with Non-Metastatic Castration-Resistant Prostate Cancer

  2. Pfizer shares rise 1.4% after news of positive late-stage cancer trial

    Pfizer shares rise 1.4% after news of positive late-stage cancer trial

  3. Pfizer Presents Positive Pivotal Data for PF-05280014, an Investigational Biosimilar to Herceptin® (trastuzumab), at the European Society for Medical Oncology (ESMO) 2017 Congress

    Pfizer Presents Positive Pivotal Data for PF-05280014, an Investigational Biosimilar to Herceptin® (trastuzumab), at the European Society for Medical Oncology (ESMO) 2017 Congress

  4. Pfizer Receives FDA Approval for MYLOTARG™ (gemtuzumab ozogamicin)

    Pfizer Receives FDA Approval for MYLOTARG™ (gemtuzumab ozogamicin)

  5. Bristol-Myers Squibb and Pfizer Present Observational Real-World Data Analysis on the Effectiveness and Safety of Eliquis® (apixaban) Compared to Warfarin in Select High-Risk Patients with ...

    Bristol-Myers Squibb and Pfizer Present Observational Real-World Data Analysis on the Effectiveness and Safety of Eliquis® (apixaban) Compared to Warfarin in Select High-Risk Patients with Non-Valvular Atrial Fibrillation

  6. Bristol-Myers Squibb and Pfizer Present Investigational Eliquis® (apixaban) Data for Patients with Non-Valvular Atrial Fibrillation (NVAF) Undergoing Cardioversion

    Bristol-Myers Squibb and Pfizer Present Investigational Eliquis® (apixaban) Data for Patients with Non-Valvular Atrial Fibrillation (NVAF) Undergoing Cardioversion

  7. Amyloid Publishes Long-Term Data Analysis from Pfizer Suggesting Tafamidis Delays Progression of TTR-FAP, a Rare Disease

    Amyloid Publishes Long-Term Data Analysis from Pfizer Suggesting Tafamidis Delays Progression of TTR-FAP, a Rare Disease

  8. Pfizer Rare Disease Launches Two First-of-Its-Kind Innovative Technologies for People Living with Hemophilia at National Hemophilia Foundation Annual Meeting

    Pfizer Rare Disease Launches Two First-of-Its-Kind Innovative Technologies for People Living with Hemophilia at National Hemophilia Foundation Annual Meeting

  9. Global Angina Pectoris Drugs Market 2017-2021: Key Players are AstraZeneca, Gilead, Novartis & Pfizer - Research and Markets

    Global Angina Pectoris Drugs Market 2017-2021: Key Players are AstraZeneca, Gilead, Novartis & Pfizer - Research and Markets

12345

©2017 Morningstar Advisor. All right reserved.